Previous 10 | Next 10 |
A prior Phase IIa clinical trial has been successfully concluded and met study end points Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer an...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s Vice President of Business Development Dr. Sari Fis...
Can-Fite Biopharma (CANF): Q1 GAAP EPS of $0.00 beats by $0.19.Revenue of $0.15M (-25.0% Y/Y) misses by $0.15M.Shares +2.80% PM.Press Release For further details see: Can-Fite Biopharma EPS beats by $0.19, misses on revenue
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2021. Clinical D...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s CEO Dr. Pnina Fishman will present at Benzinga ...
Can-Fite BioPharma (CANF) announces that 75% of patients have been enrolled in its Phase III Comfort study designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla) in patients with moderate to severe plaque psoriasis.Enrol...
Prompted by positive interim analysis data Can-Fite accelerates patient enrollment Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...
The Phase II Study is under FDA Protocol and data are expected Q4 2021 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, t...
Can-Fite BioPharma (CANF) announces that it has initiated a series of preclinical studies required by health regulators for the marketing applications of the company's psoriasis and liver cancer treatments.Can-Fite shares up more than 7% premarket.The company's piclidenoson tre...
Kansas City Southern (KSU) +16% on $34B bid from Canadian National.Liquid Media Group Ltd. (YVR) +13% on introduction of its NFT Platform.Obalon Therapeutics (OBLN) +11%.22nd Century Group (XXII) +10%.9 Meters Biopharma (NMTR) +8%.Fisker (FSR) +7% as BAC begins coverage with a ...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Patent has already been issued in other major markets including the U.S. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced i...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled ...
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...